Dov Elefant - 25 Jan 2022 Form 4 Insider Report for Cellectar Biosciences, Inc. (CLRB)

Reporting relationship: Chief Financial Officer
Issuer ticker: CLRB
Reported as of: 25 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jan 2022, 15:06:06 UTC
Next SEC filing: 01 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Christina Blakley, attorney-in-fact for Dov Elefant

Key filing fact

Dov Elefant filed Form 4 for Cellectar Biosciences, Inc. (CLRB) on 27 Jan 2022.

Key facts

This page summarizes Dov Elefant's Form 4 filing for Cellectar Biosciences, Inc. (CLRB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Jan 2022, 15:06.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLRB transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +422,000
Change %
Price: $0.000000
Shares after: 422,000
Date: 25 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 422,000
Exercise price: $0.5500
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date.